New HIV/AIDS drug will be offered through Brazil’s SUS
A medicine that combines tenofovir (Gilead’s Viread) and lamivudine (GlaxoSmithKline’s Combivir) used to treat patients with HIV/AIDS is expected to be distributed through Brazil's Unified Health system (SUS) by the end of this month, writes Juliane Carvalho on Brazil Pharma News.
Brazil’s Institute of Drug Technology (Farmaguinhos), in partnership with drugmaker Blanver Farmoquimica, is awaiting National Health Surveillance Agency (ANVISA) approval to manufacture the drug in the country.
The arrival of the combined product to SUS has been long awaited. In 2012 a partnership for drug development was announced by Blanver's president, Sergio Frangioni. The product offering was expected to take place in the second half of 2013. He says that the company filed an application for registration of the drug with ANVISA in October 2012 and market approval was granted in December of 2012.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze